Asclepix Therapeutics, Inc.
AsclepiX Therapeutics Announces $35 Million Series A Financing
Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials
Series A financing led by the Perceptive Xontogeny Venture Fund
June 24, 2020